Factor IX is the precursor of a serine protease that functions in the intrinsic blood clotting pathway1. Deficiencies in this plasma glycoprotein result in haemophilia B (or Christmas disease) and occur in about 1 in 30,000 males2. Patients are currently treated with fresh frozen plasma or prothrombin complex concentrates prepared from pooled plasma from normal individuals. There are several problems with this method of treatment, including the probable exposure of the patients to contaminants such as the viral agents responsible for hepatitis and AIDS (acquired immune deficiency syndrome). As a first step towards an alternative source of pure human factor IX, we report here on the use of recombinant DNA techniques to produce biologically active factor IX in cultured mammalian cells. Stable cell lines were produced by co-transfecting a baby hamster kidney (BHK) cell line with a plasmid containing a gene for factor IX and a plasmid containing a selectable marker. Protein secreted by these cell lines reduces the clotting time of plasma from factor IX-deficient patients. We present additional evidence that this protein is authentic human factor IX.
Access optionsAccess options
Subscribe to Journal
Get full journal access for 1 year
only $3.90 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Jackson, C. M. & Nemerson, Y. A. Rev. Biochem. 49, 765–811 (1980).
McKee, P. A. in The Metabolic Basis of Inherited Disease (eds Stanbury, J. B., Wyngaarden, J. B., Frederickson, D. S., Goldstein, J. L. & Brown, M. S.) 1531–1560 (McGraw-Hill, New York, 1983).
Prowse, C. V. & Esnouf, M. P. Biochem. Soc. Trans. 5, 255–256 (1977).
Suttie, J. W. CRC Crit. Rev. Biochem. 8, 191–235 (1980).
Kurachi, K. & Davie, E. W. Proc. natn. Acad. Sci. U.S.A. 79, 6461–6464 (1982).
Southern, P. J. & Berg, P. J. molec. appl. Genet. 1, 327–341 (1982).
Procter, R. R. & Rapaport, S. I. Am. J. clin. Path. 36, 212–219 (1961).
Bajaj, S. P., Rapaport, S. I. & Brown, S. F. J. biol. Chem. 256, 253–259 (1981).
DiScipio, R. G., Hermodson, M. A., Yates, S. G. & Davie, E. W. Biochemistry 16, 698–706 (1977).
Buchtal, S. D. & Bell, R. G. Biochemistry 22, 1077–1082 (1983).
Graham, F. L. & van der Eb, A. J. Virology 52, 456–467 (1973).
Anson, D. S. et al. EMBO J. 3, 1053–1060 (1984).
Berkner, K. L. & Sharp, P. Nucleic Acids Res. 13, 841–857 (1985).
About this article
Biotechnology Journal (2015)
A new cell culture-based assay quantifies vitamin K 2,3-epoxide reductase complex subunit 1 function and reveals warfarin resistance phenotypes not shown by the dithiothreitol-driven VKOR assay
Journal of Thrombosis and Haemostasis (2013)
Journal of Chromatography B (2012)
Establishment of a cell line expressing recombinant factor VII and its subsequent conversion to active form FVIIa through hepsin by genetic engineering method
Vox Sanguinis (2009)